Founder and CEO Andrew Woodland describes how they made the decision to focus on inflammation for the pan-BET, which is partnered with VYNE Therapeutics. VYNE has also completed a phase 1a with Tay's oral selective BET inhibitor. Plus, how Tay is also working on a small molecule gene therapy program.
Fler avsnitt av BiotechTV - News
Visa alla avsnitt av BiotechTV - NewsBiotechTV - News med BiotechTV finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
